Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRNDM-04 is a preclinical small interfering RNA (siRNA) therapeutic candidate being developed by Sirius Therapeutics for the treatment of cardiometabolic diseases. The drug is part of the company's proprietary siRNA platform, which focuses on gene silencing for various therapeutic areas. SRNDM-04 is designed to target an undisclosed molecular mechanism and utilizes delivery technology capable of reaching tissues such as the liver, adipose tissue, heart, kidneys, or the central nervous system (CNS). It is currently in the pre-clinical/IND-enabling stage of development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SRNDM-04.